OmniAb Valuation

Is OABI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OABI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OABI ($4.07) is trading below our estimate of fair value ($8.91)

Significantly Below Fair Value: OABI is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for OABI?

Other financial metrics that can be useful for relative valuation.

OABI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue24.3x
Enterprise Value/EBITDA-8.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OABI's PS Ratio compare to its peers?

The above table shows the PS ratio for OABI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.1x
QTRX Quanterix
3.7x14.4%US$582.2m
CDXC ChromaDex
5.9x18.1%US$555.0m
CYRX Cryoport
1.7x7.5%US$393.0m
TKNO Alpha Teknova
9.2x14.1%US$340.1m
OABI OmniAb
23.6x29.1%US$530.6m

Price-To-Sales vs Peers: OABI is expensive based on its Price-To-Sales Ratio (23.6x) compared to the peer average (5.1x).


Price to Earnings Ratio vs Industry

How does OABI's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: OABI is expensive based on its Price-To-Sales Ratio (23.6x) compared to the US Life Sciences industry average (3.7x).


Price to Sales Ratio vs Fair Ratio

What is OABI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OABI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.6x
Fair PS Ratio7.3x

Price-To-Sales vs Fair Ratio: OABI is expensive based on its Price-To-Sales Ratio (23.6x) compared to the estimated Fair Price-To-Sales Ratio (7.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OABI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.07
US$9.75
+139.6%
15.2%US$12.00US$8.00n/a8
Nov ’25US$4.18
US$9.75
+133.3%
15.2%US$12.00US$8.00n/a8
Oct ’25US$4.16
US$10.00
+140.4%
13.2%US$12.00US$8.00n/a8
Sep ’25US$4.19
US$9.88
+135.7%
15.6%US$12.00US$7.00n/a8
Aug ’25US$4.48
US$9.88
+120.4%
15.6%US$12.00US$7.00n/a8
Jul ’25US$3.74
US$9.88
+164.0%
15.6%US$12.00US$7.00n/a8
Jun ’25US$4.34
US$9.88
+127.5%
15.6%US$12.00US$7.00n/a8
May ’25US$4.56
US$10.00
+119.3%
17.3%US$13.00US$7.00n/a8
Apr ’25US$5.36
US$9.75
+81.9%
14.3%US$11.00US$7.00n/a8
Mar ’25US$5.91
US$9.63
+62.9%
13.7%US$11.00US$7.00n/a8
Feb ’25US$5.92
US$9.63
+62.6%
13.7%US$11.00US$7.00n/a8
Jan ’25US$6.17
US$9.63
+56.0%
13.7%US$11.00US$7.00n/a8
Dec ’24US$4.60
US$9.50
+106.5%
16.6%US$11.00US$6.00n/a8
Nov ’24US$4.51
US$10.00
+121.7%
9.3%US$11.00US$8.00US$4.187
Oct ’24US$5.19
US$10.00
+92.7%
9.3%US$11.00US$8.00US$4.167
Sep ’24US$5.83
US$10.00
+71.5%
9.3%US$11.00US$8.00US$4.197
Aug ’24US$5.54
US$10.00
+80.5%
9.3%US$11.00US$8.00US$4.487
Jul ’24US$5.03
US$9.71
+93.1%
11.9%US$11.00US$8.00US$3.747
Jun ’24US$4.23
US$10.13
+139.4%
15.2%US$13.00US$8.00US$4.348
May ’24US$3.45
US$10.25
+197.1%
16.0%US$13.00US$8.00US$4.568
Apr ’24US$3.68
US$10.67
+189.9%
15.0%US$13.00US$8.00US$5.366
Mar ’24US$4.15
US$10.33
+149.3%
21.4%US$13.00US$6.00US$5.916
Feb ’24US$4.25
US$10.25
+141.2%
26.2%US$13.00US$6.00US$5.924
Jan ’24US$3.60
US$10.25
+184.7%
26.2%US$13.00US$6.00US$6.174
Dec ’23US$3.35
US$9.00
+168.7%
33.3%US$12.00US$6.00US$4.602

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies